226. Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
Clinical trials : 145 / Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05062902 (ClinicalTrials.gov) | January 1, 2023 | 16/9/2021 | A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management | An Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management | Interstitial Cystitis;Chronic Pain;Pelvic Floor; Relaxation;Pelvic Floor Disorders | Device: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device;Drug: Botulinum Neurotoxin | HillMed Inc. | Baylor College of Medicine;University of Houston | Not yet recruiting | 18 Years | 60 Years | Female | 46 | Early Phase 1 | United States |